Randomized clinical trials in children--ethical and methodological issues.

Area of Science:

• Clinical Research Methodology
• Pediatric Pharmacology
• Medical Ethics

Background:

• Randomized controlled trials (RCTs) are the gold standard for evaluating medical interventions, ensuring evidence-based medicine and drug approvals.
• Conducting RCTs is resource-intensive, leading to pharmaceutical industry dominance in drug development and registration.
• High-quality pediatric research is crucial to reduce off-label drug use and ensure child safety and treatment efficacy.

Purpose of the Study:

• To review the ethical and methodological considerations of RCTs in adults and pediatric populations.
• To highlight the importance of tailored pediatric research to meet regulatory requirements and ensure child well-being.
• To analyze publication trends and challenges associated with RCTs.

Main Methods:

• This narrative review synthesizes existing literature on RCT methodology and ethics.
• A quantitative analysis was performed to explore publication patterns of RCTs.
• The review specifically addresses challenges unique to pediatric clinical trials.

Main Results:

• RCTs prevent allocation bias and balance confounders, crucial for reliable research outcomes.
• Pediatric RCTs require careful attention to feasibility and ethical issues, including informed child assent and equipoise.
• Regulatory authorities support pediatric studies, obligating industry and researchers to prioritize children's best interests.

Conclusions:

• Implementing robust RCTs, especially in pediatrics, necessitates addressing ethical and practical challenges.
• Ensuring child assent and therapeutic equipoise are critical for ethical and scientifically sound pediatric drug research.
• Further research and adherence to regulatory guidelines are needed to advance pediatric evidence-based medicine.